Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors
نویسندگان: لیلا علیزاده , مارال بهرامی , کوروش مسندی شیرازی , مرتضی قوجازاده , آیدا مالک مهدوی , علیرضا خبازی اسکویی
کلمات کلیدی: COVID-19; autoimmune inflammatory diseases; TNF inhibitors.
نشریه: 56015 , 9 , 10 , 2022
| نویسنده ثبت کننده مقاله |
علیرضا خبازی اسکویی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های بافت همبند |
| کد مقاله |
79063 |
| عنوان فارسی مقاله |
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors |
| عنوان لاتین مقاله |
Clinical course and outcome of COVID-19 in patients with autoimmune inflammatory diseases under treatment with TNF inhibitors |
| ناشر |
6 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Letter to Editor |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح چهار – سایر سایت های تخصصی |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| The aim of this study was to compare the outcome of COVID-19 in TNFis treated and TNFis naïve patients with AID. The COVID-19 AID (C19-AID) cohort is a prospective cohort started on 3 April 2020. Data of patients with AID who developed COVID-19 and being followed up in the clinics of Tabriz University of Medical Sciences (TUOMS) were entered in this cohort. Inclusion criteria in our study included the following: diagnosis of AID according to the clinical criteria, disease onset before COVID-19 outbreak, and age ≥ 16. Information about developing COVID-19 was obtained by telephone or direct interview and reviewing electronic medical records. Two hundred and fifty-one patients with AID who developed COVID-19 were enrolled in the study. Forty-four patients were on TNFis and 207 patients were not on
TNFis prior to COVID-19 diagnosis. Age ≥ 65 in TNFis naïve group and smoking in the group on TNFis were significantly more common. Except for a higher frequency of anosmia in patients treated with TNFis, there were no significant differences in clinical manifestation of COVID-19 between the two groups. Eighty-three patients were hospitalized. Predictors of hospitalization in multivariate regression analysis were treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), treatment with glucocorticoids and having COVID-19 risk factors ≥ 2. Hospitalization rate in patients with inflammatory bowel diseases and seronegative spondyloarthritis was less than the other AID group.
The data from this study showed that treatment with NSAIDs, treatment with glucocorticoids, and having COVID-19 risk factors ≥ 2 were independent risk factors for hospitalization in patients with AID. Being on TNFis was not an independent predictor of lower hospitalization rate. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| jrcm-10-9.pdf | 1401/04/14 | 282082 | دانلود |